Robert Steven Sikorski
Nessuna posizione attualmente
Storia della carriera di Robert Steven Sikorski
Precedenti posizioni note di Robert Steven Sikorski
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2016 | 20/03/2017 |
| Corporate Officer/Principal | 20/03/2017 | 30/04/2017 | |
| Medimmune, Inc. | Corporate Officer/Principal | 01/12/2010 | 01/09/2014 |
| AMGEN INC. | Corporate Officer/Principal | 01/03/2006 | 01/12/2010 |
MedNav, Inc.
 MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 01/01/2003 |
Formazione di Robert Steven Sikorski
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Technology Services | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
MedNav, Inc.
MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Technology Services |
| Medimmune, Inc. | Health Technology |
